Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on advances in molecular PET in urological oncology.

Literature DB >> 27222021

Update on advances in molecular PET in urological oncology.

Kazuhiro Kitajima¹, Shingo Yamamoto², Kazuhito Fukushima³, Ryogo Minamimoto⁴, Takao Kamai⁵, Hossein Jadvar⁶.

Abstract

Integrated positron emission tomography/computed tomography (PET/CT) with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of (18)F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. (18)F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.

Entities: CellLine Chemical Disease Gene Species

Keywords: Bladder cancer; Kidney cancer; Positron emission tomography/computed tomography (PET/CT); Positron emission tomography/magnetic resonance imaging (PET/MRI); Prostate cancer; Testicular cancer; Urological cancer

Mesh：

Substances：

Year: 2016 PMID： 27222021 PMCID： PMC5412592 DOI： 10.1007/s11604-016-0553-3

Source DB: PubMed Journal: Jpn J Radiol ISSN： 1867-1071 Impact factor: 2.374

105 in total

1. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors: Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal: Radiology Date: 2010-03 Impact factor: 11.105

2. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Authors: Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal: J Nucl Med Date: 2015-06-11 Impact factor: 10.057

3. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.

Authors: Angelina Cistaro; Artor Niccoli Asabella; Pietro Coppolino; Natale Quartuccio; Corinna Altini; Mariapaola Cucinotta; Pierpaolo Alongi; Michele Balma; Silvia Sanfilippo; Ambra Buschiazzo; Arnoldo Piccardo; Margherita Fanelli; Gianmario Sambuceti; Jamshed Bomanji; Sergio Baldari; Gianni Bisi; Stefano Fanti; Giuseppe Rubini
Journal: Hell J Nucl Med Date: 2015-06-29 Impact factor: 1.102

4. 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas.

Authors: Yoshifumi Noda; Masayuki Kanematsu; Satoshi Goshima; Natsuko Suzui; Yoshinobu Hirose; Kengo Matsunaga; Hironori Nishibori; Hiroshi Kondo; Haruo Watanabe; Hiroshi Kawada; Nobuyuki Kawai; Yukichi Tanahashi; Kyongtae T Bae
Journal: Eur Radiol Date: 2015-04-09 Impact factor: 5.315

5. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy.

Authors: Tobias Maurer; Michael Souvatzoglou; Hubert Kübler; Katharina Opercan; Stefan Schmidt; Ken Herrmann; Jens Stollfuss; Gregor Weirich; Bernhard Haller; Jürgen E Gschwend; Markus Schwaiger; Bernd J Krause; Uwe Treiber
Journal: Eur Urol Date: 2011-12-14 Impact factor: 20.096

6. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.

Authors: Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Koichiro Yamakado; Takayuki Katsuura; Yoko Igarashi; Yusuke Kawanaka; Miya Mouri; Shozo Hirota
Journal: Eur J Radiol Date: 2015-12-29 Impact factor: 3.528

7. Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma.

Authors: Seiji Asai; Tetsuya Fukumoto; Nozomu Tanji; Noriyoshi Miura; Masao Miyagawa; Kenichi Nishimura; Yutaka Yanagihara; Akitomi Shirato; Yuki Miyauchi; Tadahiko Kikugawa; Masayoshi Yokoyama
Journal: Int J Clin Oncol Date: 2015-03-21 Impact factor: 3.402

Review 8. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.

Authors: Hossein Jadvar
Journal: Eur J Nucl Med Mol Imaging Date: 2013-02-22 Impact factor: 9.236

9. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.

Authors: Cristina Nanni; Riccardo Schiavina; Eugenio Brunocilla; Marco Borghesi; Valentina Ambrosini; Lucia Zanoni; Giorgio Gentile; Valerio Vagnoni; Daniele Romagnoli; Giuseppe Martorana; Stefano Fanti
Journal: Clin Genitourin Cancer Date: 2013-10-14 Impact factor: 2.872

Review 10. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.

Authors: Hsin-Yi Wang; Hueisch-Jy Ding; Jin-Hua Chen; Chih-Hao Chao; Yu-Yu Lu; Wan-Yu Lin; Chia-Hung Kao
Journal: Cancer Imaging Date: 2012-10-26 Impact factor: 3.909

10 in total

1. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.

Authors: Jingjing Zhang; Gang Niu; Lixin Lang; Fang Li; Xinrong Fan; Xuefeng Yan; Shaobo Yao; Weigang Yan; Li Huo; Libo Chen; Zhiyuan Li; Zhaohui Zhu; Xiaoyuan Chen
Journal: J Nucl Med Date: 2016-08-04 Impact factor: 10.057

2. ¹¹C-Choline-Avid but ¹⁸F-FDG-Nonavid Prostate Cancer with Lymph Node Metastases on Positron Emission Tomography.

Authors: Kazuhiro Kitajima; Kazuhito Fukushima; Shingo Yamamoto; Toshiko Yamano; Haruyuki Takaki; Koichiro Yamakado; Yukako Nakanishi; Akihiro Kanematsu; Michio Nojima; Shozo Hirota
Journal: Case Rep Oncol Date: 2016-11-07

3. ¹¹C-Choline positive but ¹⁸F-FDG negative pancreatic metastasis from renal cell carcinoma on PET.

Authors: Kazuhiro Kitajima; Kazuhito Fukushima; Shingo Yamamoto; Takashi Kato; Soichi Odawara; Haruyuki Takaki; Kaoru Kobayashi; Toshiko Yamano; Koichiro Yamakado; Yukako Nakanishi; Akihiro Kanematsu; Michio Nojima; Kazuhiro Suzumura; Etsuro Hatano; Jiro Fujimoto; Takako Kihara; Keiji Nakasho; Seiichi Hirota; Shozo Hirota
Journal: Nagoya J Med Sci Date: 2017-02 Impact factor: 1.131

4. Comparison of 11C-choline Positron Emission Tomography/Computed Tomography (PET/CT) and Conventional Imaging for Detection of Recurrent Prostate Cancer.

Authors: Yusuke Kawanaka; Kazuhiro Kitajima; Shingo Yamamoto; Yukako Nakanishi; Yusuke Yamada; Takahiko Hashimoto; Toru Suzuki; Shuken Go; Akihiro Kanematsu; Michio Nojima; Keitaro Sofue; Masakatsu Trsurusaki; Yukihisa Tamaki; Rika Yoshida; Koichiro Yamakado
Journal: Cureus Date: 2018-07-11

5. Radiobiological Characterization of ⁶⁴CuCl₂ as a Simple Tool for Prostate Cancer Theranostics.

Authors: Joana Fernandes Guerreiro; Vítor Alves; Antero José Abrunhosa; António Paulo; Octávia Monteiro Gil; Filipa Mendes
Journal: Molecules Date: 2018-11-11 Impact factor: 4.411

6. Delayed post-diuretic ¹⁸F-FDG PET/CT for preoperative evaluation of renal pelvic cancer.

Authors: Yiping Shi; Ruohua Chen; Yining Wang; Gan Huang; Qian Xia; Jianjun Liu
Journal: J Cancer Date: 2020-04-06 Impact factor: 4.207

7. Diagnostic and Therapeutic Challenges in a Patient with Ureteral Metastases from a Triple Negative Breast Cancer.

Authors: Georgia Saranti; Vasiliki Zolota; Christina Kalogeropoulou; Nikolaos Papathanasiou; Theodora Katsila; Konstantina Kitsou; Ilias Haliassos; Dimitrios Kardamakis
Journal: Curr Oncol Date: 2022-07-07 Impact factor: 3.109

Review 8. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.

Authors: Girolamo Ranieri; Ilaria Marech; Artor Niccoli Asabella; Alessandra Di Palo; Mariangela Porcelli; Valentina Lavelli; Giuseppe Rubini; Cristina Ferrari; Cosmo Damiano Gadaleta
Journal: Int J Mol Sci Date: 2017-09-09 Impact factor: 5.923

9. Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer.

Authors: Akinori Nukui; Takahiro Narimatsu; Tsunehito Kambara; Hideyuki Abe; Setsu Sakamoto; Ken-Ichiro Yoshida; Takao Kamai
Journal: BMC Cancer Date: 2018-05-02 Impact factor: 4.430

10. Delayed ¹⁸F-FDG PET/CT Appearance of Urachal Adenocarcinomas.

Authors: Lian Xu; Yiping Shi; Yining Wang; Xiang Zhou; Gan Huang; Ruohua Chen; Jianjun Liu
Journal: Contrast Media Mol Imaging Date: 2020-09-14 Impact factor: 3.161

10 in total